BIOATLA INC

BCABNASDAQ

🏆 #3824 by market capEarnings Nov 11US Equity

$3.50▲ $0.03 (+0.86%)

Live

1h—

24h▲ 0.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$6M

Small Cap

📈Revenue Growth (YoY)

-81.8%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

2.9x

Cheap

Otter Score

Weak

No chart data available for BCAB.

Trading Snapshot

Day Range: $3.46 – $3.54
52-Week Range: $3.12 – $71.50
Volume: $2.59B
Avg Volume: $3.22B
Shares Outstanding: 1.7M
Next Earnings: Oct 1, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $463,016
P/E Ratio: —
P/S Ratio: 2.9x
EPS (TTM): $-41.82
Dividend Yield: —

Why Investors Own BCAB

✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
✓Healthy economics — 76% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▼ −10.4% YoY

Gross Margin (TTM)

75.7%▲ +3.7% YoY

Operating Income (TTM)

$368,000▼ −10.4% YoY

Free Cash Flow (TTM)

$224,000▼ −10.4% YoY

About BIOATLA INC

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

🦦